XTRA:MRKPharmaceuticals
Merck KGaA Backs Hybrid Cancer Drugs And Greener Lab Consumables
Merck KGaA (XTRA:MRK) announced a collaboration with Remepy to develop Hybrid Drugs that pair pharmaceuticals with app-based digital therapeutics for rare and difficult-to-treat cancers.
The company also introduced its first bio-based solvent portfolio for high-performance liquid chromatography, aimed at supporting more sustainable laboratory operations.
For you as an investor, these moves highlight how Merck KGaA is leaning into two active themes in healthcare: digital therapeutics and...